Author
Paul B.J. Burton
Bio: Paul B.J. Burton is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Acute coronary syndrome & Anemia. The author has an hindex of 1, co-authored 1 publications receiving 565 citations.
Papers
More filters
••
TL;DR: Anemia is a powerful and independent predictor of major adverse cardiovascular events in patients across the spectrum of ACS.
Abstract: Background— In the setting of an acute coronary syndrome (ACS), anemia has the potential to worsen myocardial ischemia; however, data relating anemia to clinical outcomes in ACS remain limited. Methods and Results— We examined the association between baseline hemoglobin values and major adverse cardiovascular events through 30 days in 39 922 patients enrolled in clinical trials of ACS. After adjustment for differences in baseline characteristics and index hospitalization treatments, a reverse J-shaped relationship between baseline hemoglobin values and major adverse cardiovascular events was observed. In patients with ST-elevation myocardial infarction, when those with hemoglobin values between 14 and 15 g/dL were used as the reference, cardiovascular mortality increased as hemoglobin levels fell below 14 g/dL, with an adjusted OR of 1.21 (95% CI 1.12 to 1.30, P 17 g/dL also had ex...
603 citations
Cited by
More filters
••
TL;DR: The current guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation are based on the findings of the ESC Task Force on 12 March 2015.
Abstract: ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation : The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).
6,866 citations
••
TL;DR: This paper presents a Randomized Assessment of Acute Coronary Syndrome Treatment of Intracoronary Stenting With Antithrombotic Regimen and Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction.
Abstract: ABOARD
: Angioplasty to Blunt the Rise of Troponin in Acute Coronary Syndromes Randomized for an Immediate or Delayed Intervention
ACC
: American College of Cardiology
ACE
: angiotensin-converting enzyme
ACS
: acute coronary syndromes
ACT
: activated clotting time
ACUITY
: Acute Catheterization and Urgent Intervention Triage strategY
AF
: atrial fibrillation
AHA
: American Heart Association
APPRAISE
: Apixaban for Prevention of Acute Ischemic Events
aPTT
: activated partial thromboplastin time
ARB
: angiotensin receptor blocker
ARC
: Academic Research Consortium
ATLAS
: Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Aspirin With or Without Thienopyridine Therapy in Subjects with Acute Coronary Syndrome
BARI-2D
: Bypass Angioplasty Revascularization Investigation 2 Diabetes
BMS
: bare-metal stent
BNP
: brain natriuretic peptide
CABG
: coronary bypass graft
CAD
: coronary artery disease
CI
: confidence interval
CK
: creatinine kinase
CKD
: chronic kidney disease
CK-MB
: creatinine kinase myocardial band
COX
: cyclo-oxygenase
CMR
: cardiac magnetic resonance
COMMIT
: Clopidogrel and Metoprolol in Myocardial Infarction Trial
CPG
: Committee for Practice Guidelines
CrCl
: creatinine clearance
CRP
: C-reactive protein
CRUSADE
: Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines
CT
: computed tomography
CURE
: Clopidogrel in Unstable Angina to Prevent Recurrent Events
CURRENT
: Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent Events
CYP
: cytochrome P450
DAPT
: dual (oral) antiplatelet therapy
DAVIT
: Danish Study Group on Verapamil in Myocardial Infarction Trial
DES
: drug-eluting stent
DTI
: direct thrombin inhibitor
DIGAMI
: Diabetes, Insulin Glucose Infusion in Acute Myocardial Infarction
EARLY-ACS
: Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome
ECG
: electrocardiogram
eGFR
: estimated glomerular filtration rate
ELISA
: Early or Late Intervention in unStable Angina
ESC
: European Society of Cardiology
Factor Xa
: activated factor X
FFR
: fractional flow reserve
FRISC
: Fragmin during Instability in Coronary Artery Disease
GP IIb/IIIa
: glycoprotein IIb/IIIa
GRACE
: Global Registry of Acute Coronary Events
HINT
: Holland Interuniversity Nifedipine/Metoprolol Trial
HIT
: heparin-induced thrombocytopenia
HORIZONS
: Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction
HR
: hazard ratio
hsCRP
: high-sensitivity C-reactive protein
ICTUS
: Invasive vs. Conservative Treatment in Unstable coronary Syndromes
INR
: international normalized ratio
INTERACT
: Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment
ISAR-COOL
: Intracoronary Stenting With Antithrombotic Regimen Cooling Off
ISAR-REACT
: Intracoronary stenting and Antithrombotic Regimen- Rapid Early Action for Coronary Treatment
i.v.
: intravenous
LDL-C
: low-density lipoprotein cholesterol
LMWH
: low molecular weight heparin
LV
: left ventricular
LVEF
: left ventricular ejection fraction
MB
: myocardial band
MDRD
: Modification of Diet in Renal Disease
MERLIN
: Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes
MI
: myocardial infarction
MINAP
: Myocardial Infarction National Audit Project
MRI
: magnetic resonance imaging
NNT
: numbers needed to treat
NSAID
: non-steroidal anti-inflammatory drug
NSTE-ACS
: non-ST-elevation acute coronary syndromes
NSTEMI
: non-ST-elevation myocardial infarction
NT-proBNP
: N-terminal prohormone brain natriuretic peptide
OASIS
: Organization to Assess Strategies for Ischaemic Syndromes
OPTIMA
: Optimal Timing of PCI in Unstable Angina
OR
: odds ratio
PCI
: percutaneous coronary intervention
PENTUA
: Pentasaccharide in Unstable Angina
PLATO
: PLATelet inhibition and patient Outcomes
PURSUIT
: Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
RCT
: randomized controlled trial
RE-DEEM
: Randomized Dabigatran Etexilate Dose Finding Study In Patients With Acute Coronary Syndromes (ACS) Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin And Clopidogrel
REPLACE-2
: Randomized Evaluation of PCI Linking Angiomax to reduced Clinical Events
RIKS-HIA
: Register of Information and Knowledge about Swedish Heart Intensive care Admissions
RITA
: Research Group in Instability in Coronary Artery Disease trial
RR
: relative risk
RRR
: relative risk reduction
STE-ACS
: ST-elevation acute coronary syndrome
STEMI
: ST-elevation myocardial infarction
SYNERGY
: Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors trial
SYNTAX
: SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery
TACTICS
: Treat angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy
TARGET
: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial
TIMACS
: Timing of Intervention in Patients with Acute Coronary Syndromes
TIMI
: Thrombolysis In Myocardial Infarction
TRITON
: TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel–Thrombolysis In Myocardial Infarction
UFH
: unfractionated heparin
VKA
: vitamin K antagonist
VTE
: venous thrombo-embolism
Guidelines summarize and evaluate all available evidence, at the time of the writing process, on a particular issue with the aim of assisting physicians in selecting the best management strategies for an individual patient, with a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means. Guidelines are no substitutes but are complements for textbooks and cover the European Society of Cardiology (ESC) Core Curriculum topics. Guidelines and recommendations should help the physicians to make decisions in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible physician(s).
A great number of Guidelines have been issued in recent years by the ESC as well as by other societies and organizations. Because of the impact on clinical practice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (http://www.escardio.org/guidelines-surveys/esc-guidelines/about/Pages/rules-writing.aspx). ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated.
Members of this Task Force were selected by the ESC to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for diagnosis, management, and/or prevention of a given condition according to ESC Committee for Practice Guidelines (CPG) policy. A critical evaluation of diagnostic and therapeutic procedures was performed including assessment of the risk–benefit ratio. Estimates of expected health outcomes for larger populations were included, where data exist. The level of evidence and the strength of recommendation of particular treatment options were weighed and graded according to pre-defined scales, as outlined in Tables 1 and 2 . …
3,841 citations
••
Emory University1, University of California, San Francisco2, University of California, San Diego3, Baylor College of Medicine4, University of Minnesota5, Virginia Commonwealth University6, Rush University Medical Center7, Texas Tech University8, Duke University9, University of Texas Health Science Center at Houston10, National Institutes of Health11
TL;DR: In this article, Anderson et al. discuss the FAHA chair election process and discuss the state of the art in the field of cancer research. But they do not discuss the role of women in this process.
3,218 citations
••
TL;DR: Bleeding complications have been associated with an increased risk of subsequent adverse outcomes, including MI, stroke, stent thrombosis, and death, in patients with ACS and in those undergoing percutaneous coronary intervention (PCI) as well as in the long-term antithrombotic setting.
Abstract: Advances in antithrombotic therapy, along with an early invasive strategy, have reduced the incidence of recurrent ischemic events and death in patients with acute coronary syndromes (ACS; unstable angina, non–ST-segment–elevation myocardial infarction [MI], and ST-segment–elevation MI).1,–,4 However, the combination of multiple pharmacotherapies, including aspirin, platelet P2Y12 inhibitors, heparin plus glycoprotein IIb/IIIa inhibitors, direct thrombin inhibitors, and the increasing use of invasive procedures, has also been associated with an increased risk of bleeding.
Editorial see p 2664
Bleeding complications have been associated with an increased risk of subsequent adverse outcomes, including MI, stroke, stent thrombosis, and death, in patients with ACS and in those undergoing percutaneous coronary intervention (PCI),5,–,10 as well as in the long-term antithrombotic setting.11,12 Thus, balancing the anti-ischemic benefits against the bleeding risk of antithrombotic agents and interventions is of paramount importance in assessing new therapies and in managing patients. Prior randomized trials comparing antithrombotic agents suggest that a reduction in bleeding events is associated with improved survival.13,14
Because prevention of major bleeding may represent an important step in improving outcomes by balancing safety and efficacy in the contemporary treatment of ACS, bleeding events have been systematically identified as a crucial end point for the assessment of the safety of drugs during the course of randomized clinical trials, and are an important aspect of the evaluation of new devices and interventional therapies.15 Unlike ischemic clinical events (eg, cardiac death, MI, stent thrombosis), for which there is now general consensus on end-point definitions,16,17 there is substantial heterogeneity among the many bleeding definitions currently in use. Lack of standardization makes it difficult to optimally organize key clinical trial processes such as adjudication, and even more difficult to interpret relative …
3,215 citations
••
2,434 citations